Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
3.600
-0.050 (-1.37%)
Feb 5, 2026, 4:00 PM EST - Market closed

Relmada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
26416125105625521
Market Cap Growth
2137.30%-87.41%18.63%-83.18%19.93%-6.06%
Enterprise Value
250-3818-79537398
Last Close Price
3.600.524.143.4922.5332.07
PB Ratio
12.620.441.460.753.004.93
P/TBV Ratio
27.890.441.460.753.004.93
Quick Ratio
2.684.367.9011.9414.089.30
Current Ratio
2.864.458.0012.2614.839.37
Return on Equity (ROE)
-196.79%-132.33%-87.51%-90.07%-80.14%-53.74%
Return on Assets (ROA)
-102.41%-73.14%-51.76%-53.57%-46.01%-31.52%
Return on Capital Employed (ROCE)
-597.10%-236.10%-121.50%-114.80%-60.40%-56.20%
Earnings Yield
-21.28%-509.73%-79.28%-149.50%-20.13%-11.42%
FCF Yield
-15.15%-329.85%-41.46%-98.81%-14.71%-5.34%
Buyback Yield / Dilution
-5.32%-0.21%-1.59%-68.80%-12.56%-68.97%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q